HS
HighVista Strategies Portfolio holdings
AUM
$272M
This Quarter Return
+14.9%
1 Year Return
+24.34%
3 Year Return
+176.43%
5 Year Return
+271.23%
10 Year Return
+682.63%
AUM
$272M
AUM Growth
+$272M
(+4.9%)
Cap. Flow
-$12.8M
Cap. Flow
% of AUM
-4.69%
Top 10 Holdings %
Top 10 Hldgs %
27.33%
Holding
177
New
29
Increased
50
Reduced
55
Closed
31
Top Buys
| 1 |
Viridian Therapeutics
VRDN
|
$4.25M |
| 2 |
Advanced Micro Devices
AMD
|
$2.19M |
| 3 |
Celldex Therapeutics
CLDX
|
$2.17M |
| 4 |
Ferguson
FERG
|
$2.15M |
| 5 |
Mineralys Therapeutics
MLYS
|
$2.03M |
Top Sells
| 1 |
Albertsons Companies
ACI
|
$4.15M |
| 2 |
GE Vernova
GEV
|
$3.07M |
| 3 |
SWTX
SpringWorks Therapeutics
SWTX
|
$3.03M |
| 4 |
Alphabet (Google) Class C
GOOG
|
$2.1M |
| 5 |
Bausch Health
BHC
|
$2.03M |
Sector Composition
| 1 | Healthcare | 37.62% |
| 2 | Technology | 22.09% |
| 3 | Industrials | 8.52% |
| 4 | Financials | 6.08% |
| 5 | Consumer Discretionary | 5.13% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
101
Axsome Therapeutics
AXSM
$6.09B
| $1.14M | 0.42% |
10,909
-10,594
| -49% | -$1.11M |
|
102
Shift4
FOUR
$6.06B
| $1.12M | 0.41% |
+11,300
| New | +$1.12M |
|
103
Scholar Rock
SRRK
$3.3B
| $1.11M | 0.41% |
31,230
| – | – |
|
104
LKQ Corp
LKQ
$8.23B
| $1.09M | 0.4% |
29,500
-7,200
| -20% | -$266K |
|
105
Vaxcyte
PCVX
$4.17B
| $1.09M | 0.4% |
33,457
+355
| +1% | +$11.5K |
|
106
Soleno Therapeutics
SLNO
$3.56B
| $1.08M | 0.4% |
12,941
-1,403
| -10% | -$118K |
|
107
HDFC Bank
HDB
$181B
| $1.02M | 0.37% |
13,241
-5,000
| -27% | -$383K |
|
108
HubSpot
HUBS
$24.9B
| $1M | 0.37% |
1,800
| – | – |
|
109
MoonLake Immunotherapeutics
MLTX
$3.78B
| $989K | 0.36% |
20,953
-22,588
| -52% | -$1.07M |
|
110
ICICI Bank
IBN
$113B
| $977K | 0.36% |
29,047
-9,700
| -25% | -$326K |
|
111
Vera Therapeutics
VERA
$1.47B
| $954K | 0.35% |
40,473
-11,724
| -22% | -$276K |
|
112
Autoliv
ALV
$9.56B
| $951K | 0.35% |
+8,500
| New | +$951K |
|
113
Edgewise Therapeutics
EWTX
$1.54B
| $914K | 0.34% |
69,723
-21,484
| -24% | -$282K |
|
114
Ocular Therapeutix
OCUL
$2.25B
| $825K | 0.3% |
88,876
+3,635
| +4% | +$33.7K |
|
115
Keros Therapeutics
KROS
$640M
| $702K | 0.26% |
52,618
+511
| +1% | +$6.82K |
|
116
Madrigal Pharmaceuticals
MDGL
$9.7B
| $698K | 0.26% |
2,305
+94
| +4% | +$28.4K |
|
117
Roivant Sciences
ROIV
$8.6B
| $690K | 0.25% |
61,268
-54,058
| -47% | -$609K |
|
118
Natera
NTRA
$23B
| $678K | 0.25% |
4,014
+164
| +4% | +$27.7K |
|
119
GH Research
GHRS
$870M
| $637K | 0.23% |
+52,247
| New | +$637K |
|
120
JD.com
JD
$44.2B
| $626K | 0.23% |
19,183
+8,000
| +72% | +$261K |
|
121
Kanzhun
BZ
$11.1B
| $560K | 0.21% |
31,400
+19,500
| +164% | +$348K |
|
|
CNTA
122
Centessa Pharmaceuticals
CNTA
$2.13B
| $535K | 0.2% |
40,684
+1,664
| +4% | +$21.9K |
|
123
Evolus
EOLS
$477M
| $535K | 0.2% |
+58,042
| New | +$535K |
|
124
Corbus Pharmaceuticals
CRBP
$121M
| $520K | 0.19% |
75,292
| – | – |
|
125
Relay Therapeutics
RLAY
$709M
| $518K | 0.19% |
+149,701
| New | +$518K |
|